← back to search

Alan L. Chang

Stanford Medicine · US
Area of research
Immunology · Oncology
Research interest
Research interests include Immune cells in cancer, Neuroinflammation and Neurodegeneration Mechanisms, Cancer Immunotherapy and Biomarkers, and Chemokine receptors and signaling.
h-index
28
citations
3,785
works
126
NIH funding
primary concept
email

Recent publications

A machine learning model for frailty based on wearable device measurements
Communications Medicine 2026cited by 0position: middledoi
RETRACTED: 60 Predicting chorioamnionitis using AI-based methods: a retrospective cohort study
American Journal of Obstetrics and Gynecology 2024cited by 0position: middledoi
Whole genome deconvolution unveils Alzheimer’s resilient epigenetic signature
Nature Communications 2023cited by 23position: middledoi
Prediction of neuropathologic lesions from clinical data
Alzheimer s & Dementia 2023cited by 16position: middledoi
Revealing the impact of lifestyle stressors on the risk of adverse pregnancy outcomes with multitask machine learning
Frontiers in Pediatrics 2022cited by 6position: middledoi
Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate
Scientific Reports 2017cited by 35position: middledoi
Anti-GITR therapy promotes immunity against malignant glioma in a murine model
Cancer Immunology Immunotherapy 2016cited by 40position: middledoi
Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters
Journal of Translational Medicine 2016cited by 18position: middledoi
Dendritic Cell–Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma
The Journal of Immunology 2015cited by 63position: middledoi
Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy
OncoImmunology 2015cited by 31position: middledoi
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Clinical Cancer Research 2014cited by 577position: middledoi
The role of IDO in brain tumor immunotherapy
Journal of Neuro-Oncology 2014cited by 106position: middledoi
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
Frontiers in Immunology 2013cited by 131position: middledoi
Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model
Journal of Neuroimmunology 2013cited by 20position: middledoi
IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Clinical Cancer Research 2012cited by 465position: middledoi

Grants

Conference: Summer Symposium in Real Analysis 48
NSF2606135$23,0002026–2027PIRePORTER
Kakeya sets and rectifiability
NSF2247233$180,4672023–2026PIRePORTER

Frequent collaborators

Maciej S. Lesniak · Northwestern University10 papers (2012–2017)Mahua Dey · University of Wisconsin–Madison6 papers (2013–2015)Derek A. Wainwright · Loyola University Chicago6 papers (2012–2015)Jason Miska · Northwestern University5 papers (2015–2017)Lingjiao Zhang · Warren County Community College5 papers (2014–2016)Jian Qiao · Southwestern Medical Center4 papers (2014–2016)Irina V. Balyasnikova · Northwestern University4 papers (2012–2015)Yu Han · Northwestern University4 papers (2014–2017)Atique U. Ahmed · Northwestern University4 papers (2012–2016)Nima Aghaeepour · Palo Alto University3 papers (2023–2024)Camilo Espinosa · Massachusetts Institute of Technology3 papers (2023–2026)Eloïse Berson · Palo Alto University3 papers (2023–2024)Samson Mataraso · Palo Alto University3 papers (2023–2024)Julius W. Kim · Neurological Surgery3 papers (2014–2016)Yu Han · Hong Kong Polytechnic University3 papers (2012–2015)Neal G. Ravindra · Xalud Therapeutics (United States)3 papers (2023–2026)Thanaphong Phongpreecha · Palo Alto University3 papers (2023–2026)Alex L. Tobias · University of Minnesota Medical Center3 papers (2012–2015)Kathleen S. Montine · Stanford University2 papers (2023–2023)Martin Becker · Palo Alto University2 papers (2023–2023)